SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback